AT317250B - Verfahren zur Herstellung von neuen Silbercycloheptaamylose-Einschlußverbindungen - Google Patents

Verfahren zur Herstellung von neuen Silbercycloheptaamylose-Einschlußverbindungen

Info

Publication number
AT317250B
AT317250B AT296173A AT296173A AT317250B AT 317250 B AT317250 B AT 317250B AT 296173 A AT296173 A AT 296173A AT 296173 A AT296173 A AT 296173A AT 317250 B AT317250 B AT 317250B
Authority
AT
Austria
Prior art keywords
preparation
inclusion compounds
new silver
cycloheptaamylose
cycloheptaamylose inclusion
Prior art date
Application number
AT296173A
Other languages
German (de)
English (en)
Original Assignee
Trommsdorff Fa H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trommsdorff Fa H filed Critical Trommsdorff Fa H
Application granted granted Critical
Publication of AT317250B publication Critical patent/AT317250B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT296173A 1972-12-11 1973-04-04 Verfahren zur Herstellung von neuen Silbercycloheptaamylose-Einschlußverbindungen AT317250B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2260536A DE2260536C3 (de) 1972-12-11 1972-12-11 MolekiileinschluBverbindungen aus einem Silberalkanolammin-Komplex und beta-Cycloheptaamylose, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
AT317250B true AT317250B (de) 1974-08-26

Family

ID=5864075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT296173A AT317250B (de) 1972-12-11 1973-04-04 Verfahren zur Herstellung von neuen Silbercycloheptaamylose-Einschlußverbindungen

Country Status (14)

Country Link
US (1) US3911115A (US06724976-20040420-M00002.png)
JP (1) JPS49133512A (US06724976-20040420-M00002.png)
AT (1) AT317250B (US06724976-20040420-M00002.png)
BE (1) BE808464A (US06724976-20040420-M00002.png)
CA (1) CA1010854A (US06724976-20040420-M00002.png)
CH (1) CH590880A5 (US06724976-20040420-M00002.png)
DE (1) DE2260536C3 (US06724976-20040420-M00002.png)
ES (1) ES421313A1 (US06724976-20040420-M00002.png)
GB (1) GB1433828A (US06724976-20040420-M00002.png)
HU (1) HU166786B (US06724976-20040420-M00002.png)
NL (1) NL7316976A (US06724976-20040420-M00002.png)
SE (1) SE409461B (US06724976-20040420-M00002.png)
SU (1) SU520906A3 (US06724976-20040420-M00002.png)
ZA (1) ZA738976B (US06724976-20040420-M00002.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU180183B (en) * 1980-12-19 1983-02-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing stable suppository compositions containing volatile and/or labile active substances
IL76889A0 (en) * 1984-11-02 1986-02-28 Johnson Matthey Plc Solubilised platinum compound,method for the production thereof and pharmaceutical compositions containing the same
BE1004467A3 (nl) * 1990-06-18 1992-11-24 Sollie Philippe Stikstof- en zilverhoudend derivaat.
TW224049B (US06724976-20040420-M00002.png) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
AU5153399A (en) 1998-08-14 2000-03-06 Coloplast A/S Stabilised compositions having antibacterial activity
US6027469A (en) * 1998-12-03 2000-02-22 Johnson; Lee D. Disinfecting system for hemodialysis apparatus
ATE282957T1 (de) * 2000-09-29 2004-12-15 Coloplast As Stabilisierte zusammensetzungen mit antibakterieller wirkung
US20030185889A1 (en) * 2002-03-27 2003-10-02 Jixiong Yan Colloidal nanosilver solution and method for making the same
US20040180093A1 (en) * 2003-03-12 2004-09-16 3M Innovative Properties Company Polymer compositions with bioactive agent, medical articles, and methods
US7285576B2 (en) 2003-03-12 2007-10-23 3M Innovative Properties Co. Absorbent polymer compositions, medical articles, and methods
US20050123590A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Wound dressings and methods
US7745509B2 (en) 2003-12-05 2010-06-29 3M Innovative Properties Company Polymer compositions with bioactive agent, medical articles, and methods
US20050123621A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Silver coatings and methods of manufacture
US8399027B2 (en) 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
US20070166399A1 (en) 2006-01-13 2007-07-19 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
US20100098949A1 (en) * 2006-10-18 2010-04-22 Burton Scott A Antimicrobial articles and method of manufacture
US8734876B2 (en) * 2009-12-29 2014-05-27 David A. French Confectionary product and method of manufacture and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923704A (en) * 1957-05-15 1960-02-02 Hoffmann La Roche Cycloamylose sulfates and derivatives thereof
US3122534A (en) * 1958-02-04 1964-02-25 Avebe Coop Verkoop Prod Amylose derivatives

Also Published As

Publication number Publication date
AU6307373A (en) 1975-06-05
BE808464A (fr) 1974-03-29
SE409461B (sv) 1979-08-20
GB1433828A (en) 1976-04-28
SU520906A3 (ru) 1976-07-05
DE2260536B2 (de) 1974-12-05
CH590880A5 (US06724976-20040420-M00002.png) 1977-08-31
CA1010854A (en) 1977-05-24
ZA738976B (en) 1974-11-27
HU166786B (US06724976-20040420-M00002.png) 1975-05-28
DE2260536A1 (de) 1974-07-04
NL7316976A (US06724976-20040420-M00002.png) 1974-06-13
ES421313A1 (es) 1976-04-16
US3911115A (en) 1975-10-07
DE2260536C3 (de) 1975-07-10
JPS49133512A (US06724976-20040420-M00002.png) 1974-12-21

Similar Documents

Publication Publication Date Title
AT340590B (de) Verfahren zur herstellung von neuen 7-acylaminocephalosporinderivaten
AT329076B (de) Verfahren zur herstellung von neuen 1-aminouracilen
AT331258B (de) Verfahren zur herstellung von neuen 1,2,3-oxathiazin-4-onen
AT317250B (de) Verfahren zur Herstellung von neuen Silbercycloheptaamylose-Einschlußverbindungen
AT330791B (de) Verfahren zur herstellung von neuen phenylcarbamoylpyrazolinverbindungen
AT325605B (de) Verfahren zur herstellung von neuen alpha-phenylindolderivaten
AT324312B (de) Verfahren zur herstellung von neuen trifluormethylsalicylaniliden
AT321317B (de) Verfahren zur Herstellung von neuen quaternären N-Allophanoylmethylammoniumverbindungen
AT330955B (de) Verfahren zur herstellung von neuen beta-lactamen
AT324333B (de) Verfahren zur herstellung von neuen substituierten 5-chromanolen
AT330766B (de) Verfahren zur herstellung von neuen sulfamoylphenylimidazolidinonderivaten
AT323750B (de) Verfahren zur herstellung von neuen nitroimidazolyl-triazolc-pyridazinen
AT325029B (de) Verfahren zur herstellung von neuen 2'-fluor-biphenylylen
AT323189B (de) Verfahren zur herstellung von neuen lactamen
AT331805B (de) Verfahren zur herstellung von neuen triazinobenzimidazolen
AT326115B (de) Verfahren zur herstellung von neuen 5-acylpyrrolderivaten
AT316747B (de) Verfahren zur Herstellung von neuen Alkyl-7-deoxy-7-mercaptoalkylthio-α-thiolincosaminiden
AT315166B (de) Verfahren zur Herstellung von neuen 2-Acyl-5-nitrothiazolen
AT332400B (de) Verfahren zur herstellung von neuen 4-phenylaminopyridinderivaten
AT333740B (de) Verfahren zur herstellung von neuen indanderivaten
AT324347B (de) Verfahren zur herstellung von neuen substituierten azetidin-2-onen
AT330182B (de) Verfahren zur herstellung von neuen tetrahydroisochinolindionderivaten
AT329060B (de) Verfahren zur herstellung von neuen tetrahydroisochinolindionderivaten
ATA226175A (de) Verfahren zur herstellung von neuen tetrahydroisochinolindionderivaten
ATA238775A (de) Verfahren zur herstellung von neuen chinoxalin-di-n-oxidderivaten

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee